News Related to Vaxcyte, Inc.

Related coverage linked through entity extraction aliases.

FDA Reverses Decision, Will Review Moderna's mRNA Flu Vaccine

Jul 22, 2026

The FDA has agreed to review Moderna's mRNA flu vaccine after initially rejecting it, with a decision expected by August 2026. The reversal occurs amid a contraction in the vaccine sector, with funding drops and layoffs under the Trump administration.

Vaxcyte Launches VAX-31 Phase 3 Program, Targets Adult BLA Filing by End of 2027

Feb 15, 2026

Vaxcyte has initiated its Phase 3 adult program for VAX-31, a 31-valent pneumococcal conjugate vaccine, with the pivotal OPUS-1 trial enrolling 4,000 adults aged 50 and older. The company plans to submit a Biologics License Application by the end of next year.